Who
Michael P. Dube
VP, Chief Accounting Officer
Company insider
Files Form 4 as: VP, Chief Accounting Officer, Intellia Therapeutics.
In numbers
- Trades disclosed
- 13
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $279K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jul 2024
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $23K1,864 at $12.43 | filing |
| 1 Jul 2026filed 6 Jul 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $44K2,641 at $16.78 | filing |
| 1 Jul 2026filed 6 Jul 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $44K2,641 at $16.78 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —17,250 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —17,250 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $28K2,989 at $9.21 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $28K2,989 at $9.21 | filing |
| 1 Oct 2025filed 3 Oct 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $33K1,871 at $17.38 | filing |
| 2 Jul 2025filed 3 Jul 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $25K2,503 at $9.95 | filing |
| 1 Mar 2025filed 4 Mar 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $17K1,372 at $12.18 | filing |
| 2 Oct 2024filed 4 Oct 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $38K2,012 at $19.01 | filing |
| 1 Jul 2024filed 3 Jul 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —17,801 at $0.00 | filing |
News
Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsNTLA · rttnews.com · 13 Oct 2026
0 headlines in the last 90 days name Michael P. Dube; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.